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Introduction
Bacterial infections remain the leading killer worldwide
which is worsened by the continuous emergence of anti-
biotic resistance. In particular, antibiotic resistant Gram-
negative bacteria are prevalent and extremely difficult to
treat. Therefore, rejuvenating the therapeutic potentials
of existing antibiotics represents an attractive novel
strategy. Antimicrobial peptides have been of great focus
recently. Newly derived synthetic lipopeptides have been
shown to exhibit antimicrobial activity against bacteria
and fungi.
Objectives
In this study, we investigated the ability of an antimicro-
bial peptide, PA-KKkK, to enhance the potency of cur-
rently used antibiotics against antibiotic-resistant clinical
isolates of Escherichia coli and a NDM-1 producing
strain.
Methods
Antibiotic susceptibility was investigated by determining
the minimal inhibitory concentration (MIC) using a
broth dilution method. To study the combined interac-
tions between PA-KKkK and the antibiotics, chequer-
board titrations were performed. Time-kill assays were
then carried out to prove the effect of synergistic activity
against the tested bacterial strains. Transmembrane
potential depolarisation assays and ATP levels were
determined to understand the mechanism of action of
PA-KKkK.
Results
NDM-1 producing strain was extremely resistant to all
antibiotics tested. The factional inhibitory concentration
index (FICI) was calculated to show the peptide syner-
gised with rifampicin against the NDM-1 strain, while it
synergised with rifampicin, colistin, ceftazidime and
aztreonam against antibiotic-resistant clinical isolate of
E. coli. Time-kill analysis demonstrated significant
synergistic activities when a low level of PA-KKkK was
combined with rifampicin and colistin. PA-KKkK had a
membranolytic effect on cytoplasmic membrane and in
combination, decreased ATP levels of cells in a dose-
dependent manner.
Conclusion
We have demonstrated that PA-KKkK acts as an antibiotic
enhancer and therefore accelerates the bactericidal activity
of drugs against antibiotic-resistant E. coli. This novel
treatment regimen can have major clinical implications in
our fight against Gram-negative bacterial infections.
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